Patents by Inventor Liangxing Wu

Liangxing Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tricyclic heterocyclic compounds as sting activators
    Patent number: 11713317
    Abstract: The present application provides tricyclic heterocyclic compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: March 2, 2021
    Date of Patent: August 1, 2023
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Neil Lajkiewicz, Yingda Ye, Zhenwu Li, Wenqing Yao
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20230226062
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds inhibit PD-1/PD-L1 interaction and are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: September 26, 2022
    Publication date: July 20, 2023
    Inventors: Liangxing Wu, Ding-Quan Qian, Liang Lu, Neil Lajkiewicz, Leah C. Konkol, Zhenwu Li, Fenglei Zhang, Jingwei Li, Haisheng Wang, Meizhong Xu, Kaijiong Xiao, Wenqing Yao
  • Naphthyridinone compounds as JAK2 V617F inhibitors
    Patent number: 11691971
    Abstract: The present application provides naphthyridinone compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: July 4, 2023
    Assignee: Incyte Corporation
    Inventors: Stacey Shepard, Lixin Shao, Liangxing Wu, Wenqing Yao
  • SPIRO COMPOUNDS AS INHIBITORS OF KRAS
    Publication number: 20230192696
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: November 3, 2022
    Publication date: June 22, 2023
    Inventors: Le ZHAO, Xiaozhao WANG, Wenyu ZHU, Haolin YIN, Liangxing WU, Wenqing YAO
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20230192689
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: February 16, 2023
    Publication date: June 22, 2023
    Inventors: Zhenwu Li, Liangxing Wu, Wenqing Yao
  • Heterocyclic compounds as immunomodulators
    Patent number: 11673883
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: June 13, 2023
    Assignee: Incyte Corporation
    Inventors: Liang Lu, Ding-Quan Qian, Liangxing Wu, Wenqing Yao
  • Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
    Patent number: 11673894
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: June 13, 2023
    Assignee: Incyte Corporation
    Inventors: Xiaozhao Wang, Pei Gan, Taisheng Huang, Chao Qi, Ding-Quan Qian, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Fenglei Zhang, Le Zhao, Chunhong He
  • Bicyclic heterocycles as FGFR4 inhibitors
    Patent number: 11667635
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: June 6, 2023
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Liang Lu, Liangxing Wu, Ding-Quan Qian, Wenqing Yao
  • Tricyclic urea compounds as JAK2 V617F inhibitors
    Patent number: 11661422
    Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Grant
    Filed: August 26, 2021
    Date of Patent: May 30, 2023
    Assignee: Incyte Corporation
    Inventors: Kai Liu, Brent Douty, Daniel Levy, Liangxing Wu, Wenqing Yao, Eddy W. Yue
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20230146129
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: December 27, 2022
    Publication date: May 11, 2023
    Inventors: Liangxing Wu, Bo Shen, Meizhong Xu, Wenqing Yao
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20230100875
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: November 22, 2022
    Publication date: March 30, 2023
    Inventors: Neil Lajkiewicz, Liangxing Wu, Wenqing Yao
  • Heterocyclic compounds as immunomodulators
    Patent number: 11613536
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: March 28, 2023
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Fenglei Zhang, Song Mei, Wenqing Yao
  • Heterocyclic compounds as immunomodulators
    Patent number: 11608337
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: March 21, 2023
    Assignee: Incyte Corporation
    Inventors: Zhenwu Li, Liangxing Wu, Wenqing Yao
  • PD-L1/STING conjugates and methods of use
    Patent number: 11596692
    Abstract: The present application relates to conjugates of STING agonists and small molecule modulators of the PD-1/PD-L1 protein/protein interaction, as well as methods of treating cancer using the conjugates.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: March 7, 2023
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Zhenwu Li, Wenqing Yao
  • Heterocyclic compounds as immunomodulators
    Patent number: 11572366
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: February 7, 2023
    Assignee: Incyte Corporation
    Inventors: Jingwei Li, Liangxing Wu, Wenqing Yao
  • Heterocyclic compounds as immunomodulators
    Patent number: 11566026
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: September 15, 2020
    Date of Patent: January 31, 2023
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Bo Shen, Meizhong Xu, Wenqing Yao
  • IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS
    Publication number: 20230024173
    Abstract: The present application provides imidazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: July 29, 2022
    Publication date: January 26, 2023
    Inventors: Qinda Ye, Jingwei Li, Ken Mukai, Brandon Smith, Liangxing Wu, Wenqing Yao, Min Ye, Yingnan Chen, Margaret Favata, Yvonne Lo
  • BICYCLIC PYRAZOLYL AMINES AS CDK2 INHIBITORS
    Publication number: 20230002376
    Abstract: The present application provides bicyclic amines of Formula (I): or a pharmaceutically acceptable salt thereof, that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: June 21, 2022
    Publication date: January 5, 2023
    Inventors: Joshua Hummel, Jingwei Li, Ding-Quan Qian, Liangxing Wu
  • Heterocyclic compounds as immunomodulators
    Patent number: 11535615
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: December 27, 2022
    Assignee: Incyte Corporation
    Inventors: Neil Lajkiewicz, Liangxing Wu, Wenqing Yao
  • Spiro compounds as inhibitors of KRAS
    Patent number: 11530218
    Abstract: Disclosed are spirocyclic compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and treating cancer, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: January 20, 2021
    Date of Patent: December 20, 2022
    Assignee: INCYTE CORPORATION
    Inventors: Le Zhao, Xiaozhao Wang, Wenyu Zhu, Haolin Yin, Liangxing Wu, Wenqing Yao